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Juliana Martha Sáa, Takashi Nomurab, Joana dArc Nevesc, J. Kevin Bairdd,
Thomas E. Wellemsb, Hernando A. del Portilloa,*
a Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Av. Lineu Prestes 1374,
São Paulo SP, 05508-900, Brazil
b Malaria Genetics Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, USA
c Centro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil
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Abstract
We describe here the sequence of the Plasmodium vivax mdr1 gene from 10 different isolates differing in chloroquine sensitivity. The deduced
amino acid sequence of PvMDR1 shares more than 70% similarity with other malarial MDR proteins and it displays consensus motifs of an
ABC family transporter including two transmembrane domains and two ATP binding cassettes. Similarity and dendrogram analyses revealed that
sequences could be grouped according to their geographical origin. Within each geographical group however, no correlation was found between chlo-
roquine resistance and specific mutations.
 2005 Elsevier Inc. All rights reserved.
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Plasmodium vivax is the most widely distributed human malarial
parasite outside sub-Saharan Africa and responsible for 70–80 million
clinical cases annually (Mendis et al., 2001). Despite its major socio-
economical burden, research in P. vivax remains largely neglected
due to the lack of a continuous in vitro culture and the low parasite-
mias associated with natural infections.
Drug resistance is a major factor in the present resurgence of
malaria worldwide. Several genes have now been related to drug resis-
tance in Plasmodium falciparum, which causes the most lethal form of
human malaria: pfdhfr and pfdhps, where point mutations confer resis-
tance to dihydrofolate reductase inhibitors (Cowman et al., 1988; Pet-
erson et al., 1988) and sulfadoxine (Brooks et al., 1994; Triglia and
Cowman, 1994), respectively; cytochrome b gene in which the point
mutation Y268S can be rapidly selected by atovaquone monotherapy
(Korsinczky et al., 2000; Srivastava and Vaidya, 1999); pfcrt, which
contains specific mutations associated with chloroquine resistance
(CQR) (Fidock et al., 2000); pfmdr1 and pfmdr2 which encode P-glyco-
proteins from the ABC (ATP binding cassette) transporters family
(Foote et al., 1989; Wilson et al., 1989; Zalis et al., 1993), and some
other transporters that may be involved in chloroquine and quinine
resistance (Mu et al., 2003).
Orthologous genes of pfdhfr and pfcrt have been described in
P. vivax, namely pvdhfr (Eldin de Pecoulas et al., 1998), where point
mutations are also associated with resistance against dihydrofolate
reductase inhibitors, and pvcg10 (Nomura et al., 2001), which in con-
trast to pfcrt contains no specific mutations associated with chloro-
quine resistance (CQR). The purpose of this work was to identify
the ortholog of pfmdr1 in P. vivax, to establish its primary structure
and to verify whether amino acid substitutions were associated with
CQR among isolates from different regions of the world displaying dif-
ferent phenotypes of chloroquine sensitivity.
To identify P. vivax mdr genes, the oligonucleotides 5 0-ATGA
AAAAGGATCAAAGGCAAC-3 0 (forward) and 5 0-CTACTTAGC
CAGCTTGACGTAC-3 0 (reverse) were used in PCR amplifications
of P. vivax genomic DNA from 10 different chloroquine sensitive
(CQS) and chloroquine resistant (CQR) isolates or strains from differ-
www.elsevier.com/locate/yexpr
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ent geographical regions. Thus, three samples were from the Brazilian
Amazon State of Rondônia (RO14, RO19, ROB2, and all CQS), one
sample was from El Salvador in Central America (SalI, CQS), one
from Papua New Guinea (NGIV, CQS), one from Indonesia (IndoF,
CQR), and four from Papua (CL001, CQS; CL004, CQR; CL007,
CQS; and CL014, CQR). Thirty-five PCR cycles were performed, each
consisting of denaturation for 30 s at 94 C, renaturation for 30 s at
45 C, and elongation for 5 min at 68 C using elongase (Invitrogen).
Unique 4.5 kb DNA fragments were amplified from all samples, cloned
in pGEM T-easy plasmids (Promega) and sequenced using an ABI-
3100 automatic sequencer (Applied Biosystems). Chromatograms
and contigs were evaluated and assembled using the Phred-Phrap-Con-
sed program (http://www.phrap.org/). To guarantee the authenticity
of these sequences, all sequences were assigned a Phred value above
40. Moreover, polymorphisms were confirmed by sequencing indepen-
dent amplifications to exclude PCR artifacts. Synteny was examined
using the ACT tool (http://www.sanger.ac.uk/Software/ACT/), and
comparing a P. vivax contig containing the P. vivax mdr sequences ob-
tained from the P. vivax genome project at TIGR (http://www.tigr.
org/tdb/e2k1/pva1/) with the P. falciparum genome as annotated in
PlasmoDB (http://plasmodb.org/). GenBank Accession Nos: CL001
AY571975, CL004 AY571976, CL007 AY571977, CL014 AY571978,
IndoF_H4 AY571979, NGIV_H7 AY571980, RO14 AY571981,
RO19 AY571982, ROB2 AY571983, and SalI AY571984.
Fig. 1. Amino acid sequence comparisons of PvMDR1 and related MDR proteins. Deduced amino acid sequence of PvMDR1 from a P. vivax
isolate (pvmdr14—Accession No. AY571981) compared to MDR homologues of P. falciparum (pfmdr—Accession No. NP703574), P. chabaudi
(pcmdr—Accession No. AAM82617) and Pgp1, one of the human MDR proteins (Accession No. NP000918) and MDR3, of mouse (Accession No.
P21447). Sequences were aligned using the ClustalX program (ftp://ftp-igbmc.ustrasbg.fr/pub/ClustalX/). Predicted Transmembrane regions were
predicated with the SOUSI (Classification and Secondary Structure Prediction of Membrane Proteins) program (http://sosui.proteome.
bio.tuat.ac.jp/sosuiframe0.html) and are shown with a line over the correspondent sequence. Black shading highlights both conserved residues
and those where the amino acid substitutions are conservative. Boxes enclose potential nucleotide binding consensus sequences.
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BLASTn analysis against PlasmoDB revealed that the sequences
from all isolates shared more than 70% similarities with the P. falcipa-
rum mdr1 gene located on chromosome 5. Furthermore, deduced ami-
no acid sequences indicated an open reading frame of 4395 nucleotides
encoding a protein with predicted molecular mass of approximated
165,000 Da. BLASTP analysis showed 70, 63, and 64% similarities
with predicted proteins from P. falciparum (Accession No.
AAA29646.1), P. chabaudi (Accession No. AAM82617.1) and P. yoelii
MDR1 (Accession No. EAA22011), respectively. This analysis also re-
vealed the presence of conserved nucleotide binding sites (NBS) of the
ATP binding cassette (ABC) protein family in two halves of the mol-
ecule each of which also contained 12 predicted membrane-spanning
domains (Fig. 1). Multiple sequence alignments including MDR pro-
tein sequences from P. falciparum, P. chabaudi, and ABC transporters
from Drosophila melanogaster (CG10226-PA) and human (NP
061337.1), further confirmed that the P. vivax sequences pertain to
the ABC protein family (Fig. 1). Moreover, using the last released ver-
sion of the TIGR P. vivax genome project, a 307,346 bp contig con-
taining the P. vivax mdr sequences was identified and compared to
the homologous region of the P. falciparum genome using the ACT
tool. The results demonstrated a large degree of synteny of this genome
region between these two human malaria parasite species (not shown).
Together these data strongly suggest that this P. vivax gene encodes a
P-glycoprotein orthologue of pfmdr1 and accordingly we have termed
it pvmdr1.
Chloroquine is still the primary chemotherapeutic drug for treat-
ment of P. vivax but unfortunately resistance is emerging in several
malaria regions of the world (Wellems and Plowe, 2001). To determine
whether an association exists between point mutations of the pvmdr1
gene and CQR, similarity and dendrogram analyses were performed
using pvmdr1 sequences from isolates of different geographical regions
and with different chloroquine response (Fig. 2). Interestingly, these
analyses revealed that sequences could be grouped according to their
geographical origin and that within each geographical group resistant
isolates branched independently; yet, there was no association of ami-
no acid substitutions with CQR.
Knowledge about genetic diversity and population structure of P.
vivax remains limited (Cui et al., 2003). Studies on gene diversity
and population structure will help in predicting and monitoring the
effectiveness of intervention strategies such as the usefulness of thera-
peutic regimens, the dispersion of drug resistance, and the emergence
of multidrug-resistant parasites. For example, a direct correlation of
pvdhfr point mutations from four different allelic variants with pyri-
methamine resistance and geographic distribution of P. vivax, has been
reported (Imwong et al., 2001). In contrast, no association has been
found between point mutations of the P. vivax homolog gene of the
P. falciparum CRT and the chloroquine response of different P. vivax
isolates, including some of the samples used in the present work (Nom-
ura et al., 2001). Similarly, our results failed to detect a correlation of
pvmdr1 allele variants and CQR and are thus in agreement with results
that have not linked polymorphism of the P. falciparum mdr1 gene
with chloroquine resistance (Wellems et al., 1990). The mechanism of
CQR in P. vivax remains to be determined.
There is presently no consensus definition of drug resistance in
P. vivax; yet, it is clear that chloroquine resistance and multiple drug
resistance will spread. Genes related to pyrimethamine resistance,
pvdhfr (Eldin de Pecoulas et al., 1998; Imwong et al., 2001), chloro-
quine resistance, pvcg10 (Nomura et al., 2001) and multiple drug resis-
tance, pvmdr1 (the present work) have been characterized in P. vivax.
With the imminent release of the P. vivax genome (http://www.
tigr.org/tdb/e2k1/pva1/), and annotations facilitated through ESTs
gene discovery (Merino et al., 2003), it is likely that in silico analysis
will predict additional transporter and drug resistance genes as has
been recently reported for P. falciparum (Mu et al., 2003). Along with
the development of new technologies for P. vivax such as the short-
term in vitro cultures to monitor drug-resistance (Chotivanich et al.,
2004) it is hoped that monitoring and control strategies will help con-
trol worldwide spread of multiple drug resistant P. vivax parasites.
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Table 1S.  Pv MDR1 amino acid substitutions and chloroquine phenotypes of  the 
Plasmodium vivax isolates. CQ, chloroquine; CQS, chloroquine sensitive; CQR, chloroquine 
resistant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolate 196 237 443 500 511 556 698 783 823 908 958 976 1076 1104 1440 1447 CQ phenotype
RO14 N S I N R V G A K L M Y F L R E CQS 
RO19 N S I N R V G A K L M Y F L Q E CQS 
ROB2 N S I D R V G A K L M Y F L Q E CQS 
Sal1 N S I D R V G A K M T Y F L Q E CQS 
NGIV N S I D R V S V K L M F L L Q E CQS 
IndoF N S I D H V S A K L M F L L Q E CQR 
CL004 N S I D H V S A E L M F L F Q E CQR 
CL014 N S I D H V S A E L M F L F Q E CQR 
CL001 S P T D H V S A E L M F L F Q G CQS 
CL007 N S I D H A S A E L M F L F Q E CQS 
